Detection of Low Levels of Human Immunodeficiency Virus (HIV) May Be Critical for Early Diagnosis of Pediatric HIV Infection by Use of Dried Blood Spots

Jan Walter,1† Louise Kuhn,2 Katherine Semrau,3 Don W. Decker,1 Moses Sinkala,4§ Chipepo Kankasa,5 Donald M. Thea,3 Marc Bulterys,6‡ Chin-Yih Ou,7‡ and Grace M. Aldrovandi1*

Childrens Hospital Los Angeles, University of Southern California, Los Angeles, California1‡; Gertrude H. Sergievsky Center and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York2‡; Center for International Health and Development at the Boston University School of Public Health, Boston, Massachusetts3; Lusaka District Health Management Team, Lusaka, Zambia4§; University Teaching Hospital, University of Zambia, Lusaka, Zambia5; Global AIDS Program, U.S. Centers for Disease Control and Prevention, Lusaka, Zambia6; and Global AIDS Program, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia7

Received 21 December 2008/Returned for modification 20 April 2009/Accepted 14 July 2009

Early diagnosis of infant human immunodeficiency virus (HIV) infection is of clinical (16) and programmatic (1) importance. However, few assays have been tested for their ability to detect HIV early after transmission from dried blood spots (DBS), which is the preferred sample collection method in developing countries (15). Since levels of RNA are generally higher than those of DNA (3), and since studies of whole blood (2, 7, 13, 14) suggested enhanced detection, we hypothesized that the detection of total nucleic acid (TNA; RNA and DNA combined) would be more sensitive for early HIV diagnosis from DBS than that of DNA alone.

To test this hypothesis, we retested DBS collected from HIV-exposed infants in Zambia (5, 6) with a recently developed TNA assay. This assay performed exceedingly well on samples collected in Cameroon and Uganda (11), but it had not been fully evaluated for its ability to detect HIV infection early after breast milk transmission in infants receiving single-dose nevirapine.

DBS were collected at delivery, at 1 week, and at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, and 24 months postpartum from mother-infant pairs. A spot, consisting of 50 μL of blood, was extracted with Chelex (18) and assayed using realtime PCR (TaqMan Universal PCR master mix; Applied Biosystems, Foster City, CA) for the HIV-1 long terminal repeat gene and the beta-globin gene (17). Beta-globin gene amplification was performed in parallel on the same DNA extract to ensure an adequate number of cells in the DBS. Four- and 24-month samples were batch tested, and if they were positive, the timing of transmission was determined by systematically testing earlier samples (6). Positive results were confirmed by a second sample from a later time point. At delivery, single-dose nevirapine was provided to participants.

To test if the TNA assay might allow an earlier detection of HIV infection, we selected the last DNA-negative (DNA−) and first DNA-positive (DNA+) sample (median difference, 28 days; range, 7 to 140) from 94 infants. We also included 46 samples of infants who tested positive at delivery, as well as 50 4-month samples of infants who were negative throughout the 24-month follow-up. DBS were reextracted and tested with the TNA assay at the CDC (Atlanta) as previously described using about one-fifth of the DBS (corresponding to about 10 μL of blood) (11). DBS had been stored with desiccant at room temperature for a median of 42 months (range, 16 to 61 months) when tested using the TNA assay and a median of 29 months (range, 9 to 47 months) after the DNA testing.

Results of the TNA assay were available for 280 (99%) samples; four results (three DNA+ and one DNA−) were missing due to an insufficient amount of sample. Among the samples with available results, 5 (5%) of 93 of the last DNA− samples collected from birth to 18 months were TNA positive (TNA+) and 9 (10%) of 92 of the first DNA+ samples collected from 1 week to 21 months were TNA negative (TNA−). When restricted to one (i.e., the earliest positive) sample per infant, the sensitivity of the DNA-based assay was slightly, but not significantly, higher than that of the TNA assay (95% versus 90%; McNemar test; P = 0.19). In addition, the TNA
assay failed to detect 7 (16%) of the HIV-positive birth samples and was positive for 1 (2%) of the 50 negative 4-month samples, resulting in an overall sensitivity of 88% (95% confidence interval [CI], 83% to 94%) and a specificity of 98% (95% CI, 89% to 100%) compared to the DNA assay. Overall, both assays were discordant in the timing of transmission for 21/137 (15%) infants (Table 1).

Failure of the TNA assay to detect a positive DNA result was associated with low levels of proviral DNA as measured in the DNA real-time PCR. Median proviral DNA levels were 502 (interquartile range [IQR], 162 to 1,473) and 2,091 (IQR, 802 to 6,373) copies per 1,000,000 cell equivalents (Wilcoxon rank-sum test; \( P = 0.006 \), respectively, for TNA /DNA- (n = 16) and TNA+/DNA- (n = 117) specimens. Data were missing from 4 (3%) of the 137 DNA+ specimens. TNA assay failure was not associated with the duration between the performance of the two assays, given the good performance of the DNA assay in our hands (95% CI, 89% to 100%) compared to the DNA assay. Overall, the DNA assay’s ability to detect low levels of HIV may be due to differences in extraction efficiencies.

In summary, we found a large number of discordant samples between both assays. This is in concordance with previous publications that generally demonstrated a low sensitivity shortly after HIV exposures (4, 12). Given the clinical relevance of early infant HIV diagnosis, the ability of assays to detect low levels of HIV may be important.

This work was supported by NIH grants (R01 HD 39611 and R01 HD40777). G.M.A. is an Elizabeth Glaser Pediatric AIDS Foundation Scientist.

REFERENCES


---

**TABLE 1. Detection of HIV-1 by DNA-based and TNA-based real-time PCR analyses from DBS collected from Zambian infants**

<table>
<thead>
<tr>
<th>Infant age</th>
<th>Last DNA+ sample</th>
<th>First DNA+ sample</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of TNA+/DNA- (%)</td>
<td>No. of TNA+/DNA- (%)</td>
</tr>
<tr>
<td>Delivery</td>
<td>5/5 (100)</td>
<td>0/5 (0)</td>
</tr>
<tr>
<td>1 wk</td>
<td>42/43 (98)</td>
<td>1/43 (2)</td>
</tr>
<tr>
<td>1 mo</td>
<td>14/14 (100)</td>
<td>0/14 (0)</td>
</tr>
<tr>
<td>2 mo</td>
<td>3/4 (75)</td>
<td>1/4 (25)</td>
</tr>
<tr>
<td>3–6 mo</td>
<td>16/19 (84)</td>
<td>1/15 (7)</td>
</tr>
<tr>
<td>9 mo or later</td>
<td>8/8 (100)</td>
<td>0/8 (0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>First DNA+ sample</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of TNA+/DNA- (%)</td>
<td>No. of TNA+/DNA- (%)</td>
</tr>
<tr>
<td>Delivery</td>
<td>88/93 (95)</td>
<td>16/137 (12)</td>
</tr>
</tbody>
</table>

*The table excludes four samples (one DNA- and three DNA+) without available TNA results.

b Exact binomial (95% CI, 2 to 12%).

c Asymptotic binomial (95% CI, 83 to 94%).


